Objective The goal of this study was to investigate the role of CD 19 + B cells within the brain and spinal cord during CNS autoimmunity in a peptide-induced, primarily T-cell-mediated experimental autoimmune encephalomyelitis (EAE) model of MS. We hypothesized that CD19 + B cells outside the CNS drive inflammation in EAE.
In 1992, it was determined that the binding of leukocytes to inflamed CNS venules was inhibited by antibodies against α4-integrin. 5 Natalizumab, a humanized recombinant monoclonal antibody, was the first approved α4-integrin antagonist for treatment of relapsing forms of MS. 6 Natalizumab is highly effective in decreasing the number of CD19 + B cells in CSF. 7 The goal of this study was to investigate the role of α4-integrin ablation in CD19 + B cells in a peptide-induced, primarily T-cell-mediated experimental autoimmune encephalomyelitis (EAE) model and to identify compartment-specific contributions of B cells to disease initiation and perpetuation. A T-cellmediated EAE model was chosen to reflect the role of α4-integrin in B cells in patients with MS as closely as possible. Genetically, MS is most strongly associated with human leukcoyte antigen-DRB1*15:01, 8, 9 an association that implies a pathogenic involvement of an antigen-specific CD4 + T cell in MS.
Flow cytometry was used to phenotype leukocyte subsets in lymphoid organs and the CNS. Serum cytokine levels and immunoglobulin (Ig) levels were assessed by ELISA. B-cell adoptive transfer was used to determine the compartmentspecific pathogenic role of antigen-specific B cells.
Methods
Generation of CD19.Cre +/2 α4-integrin-deficient mice Because α4-integrin is an absolute requirement for normal organ development, α4-integrin-deficient (α −/− ) mice are embryonic lethal. 10 Thus, it is not possible to conduct EAE experiments in animals that are completely devoid of α4-integrin. To examine how the deficiency of α4-integrin affects the migration of dendritic cells and B cells into the CNS and T-cell reactivation and retention in the CNS, we used creloxP-mediated recombination 11 to create B-cell lineagespecific α4-integrin gene knockout mice. Specifically, we crossed female mice that are homozygous for the α4-integrin-floxed allele (α4 f/f ) 12 with commercially available CD19.Cre + males for the ablation of α4-integrin in B cells. Insertion of cre disrupts the CD19 coding sequence, leading to a CD19 deficiency and a concomitant reduction in germinal centers (GCs) in homozygous animals. Consequently, CD19.Cre +/+ mice behave functionally very similarly to Bcell-deficient mice. CD19.Cre +/+ mice on the C57BL/6 background were used to generate CD19.Cre +/− α4-integrin fl/fl mice that appear developmentally normal and fertile. C57BL/6 mice were purchased from (The Jackson Laboratories, Bar Harbor, MN). α4-integrin fl/fl mice were used as controls. Male and female mice were used for experiments. We observed no differences regarding disease scores, cellular composition, or any of the biochemical and cellular outcomes between the 2 sexes.
Peptides
Mouse myelin oligodendrocyte glycoprotein peptide (MOGp) Isolation of lymph node cells and splenocytes Lymph node (LN) cells and splenocytes were isolated by pressing through a 70-μM nylon mesh cell strainer as described. 13 
Percoll PLUS density gradient
In all experiments in which tissue is referred to as CNS, and not specifically as brains or spinal cords, CNS leukocytes were isolated by Percoll PLUS (GE Healthcare Bio-Sciences, Pittsburgh, PA) gradient as previously described.
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Glossary BM = bone marrow; DC = dendritic cell; EAE = experimental autoimmune encephalomyelitis; GC = germinal center; IFN = interferon gamma; IL = interleukin; LN = lymph node; MGZ = marginal zone; MOG = myelin oligodendrocyte glycoprotein; OVA = ovalbumin; PB = plasma blast; PC = plasma cell; WT = wild type.
Enzymatic CNS digestions
For some experiments, brains and spinal cords were dissociated enzymatically as described. 13 
Flow cytometry
To determine the absolute number of B cells and T cells in different compartments during EAE, multiparameter flow cytometry was used. Cells from bone marrows (BMs), spleens, LNs, brains, and spinal cords were brought into single-cell suspension as described. 13 Cells were stained for 30 minutes at 4°C with the following antibodies: CD45 PECyannin-7 (30-F11; eBioscience, San Diego, CA) CD3 Alexa Flour 700 (17A2, eBioscience), CD19 PE-Texas Red (6D5, Invitrogen, Waltham, MA), CD19 PE (1D3 BD Bioscience, San Jose, CA), CD49d FITC (PS/2, Santa Cruz Biotechnology, Dallas, TX), CD4 APC (RM4-5, BD Bioscience), CD45R B220-APC (RA3-6B2, BioLegend, San Diego, CA), PE, PE Dazzle 594, PE-Texas Red, AF700, Pac Orange, PerCP, CD138 BV421(281-2, BioLegend), CD11b (APC, APC-Cy-7, PE, PerCP/Cy5.5, V450, B700 (M1/70, BioLegend), CD23 PE-Cy7 (B3B4, BioLegend), CD5 PE-Cy5 (53-7.3, BioLegend), CD1d PE (1B1, BioLegend), GL-7 FITC (GL7, BioLegend), and CD21/CD35 BV510 (7G6, BD Bioscience, San Jose, CA). Isotype-matched mAbs were used to set the gates. Next, 30,000-300,000 gated events were acquired on an FACSAria II flow cytometer (BD Biosciences), equipped with Diva acquisition software (BD Biosciences). FlowJo (BD Biosciences) software was also used for some data analysis.
Intracellular cytokine staining
Phorbol 12-myristate 13-acetate (500 ng), ionomycin (500 ng), and GolgiPlug (1 μL) (BD Biosciences) were added to 1 × 10 6 cells and incubated for 3 hours at 37°C. Cells were then washed in phosphate-buffered saline and stained following the extracellular staining protocol for CD45-Alexa Fluor 700. After extracellular staining, CD19 + cells were purified as described and fixed using Fixation Buffer (BioLegend) for 15 minutes in the dark at room temperature. Cells were then washed with Permeabilization Buffer (BioLegend) twice and then stained using interferon gamma (IFNγ)-PE-Cy7 (BD Biosciences), interleukin (IL)-17A-FITC (BioLegend), tumor necrosis factorα-PE (eBioscience), and IL-6-APC (BioLegend). Cells were then washed, and acquired, and analyzed by flow cytometry.
ELISA Serum samples were collected by submandibular bleeding at days 13, 19 , and 29 during early active EAE, maximum EAE disease activity, and during chronic EAE. Quantitative ELISA for IL-17, IL-10, IL-4, IL-5, and IFNγ was performed using paired mAb specific for corresponding cytokines as per the manufacturer's recommendations (BD Biosciences or R&D Systems). IgM and IgG serum levels were also determined by ELISA. The results of ELISA assays are expressed as an average of triplicate wells ± SD. The EPOCH (BioTek, Winooski, VT) ELISA plate reader and software were used for data analysis (Molecular Devices Corporation, Sunnyvale, CA).
T-cell proliferation assay
To determine the capability of B cells to serve as APC to CD4 + T cells, flow cytometric proliferation assays using the green fluorescent dye carboxyfluorescein succinimidyl ester or V450 (BD Biosciences) were performed according to published methods. 15 On day 15 after active induction of EAE, spleens and LNs were harvested and processed into single-cell suspension. Splenocytes and lymphocytes were stained with carboxyfluorescein succinimidyl ester and plated at 1 × 10 6 cells per well. The cells were then restimulated with 10 μg/mL of MOG p35-55 and incubated at 37°C for 5 days. Con A at a concentration of 2 mg/mL and media were used as controls. On day 6, the cells were collected, blocked with Fc block antibody, stained with APC CD4 antibody, and acquired and analyzed by flow cytometry.
Histology
Following fixation in 10% buffered formalin, LNs were processed and embedded in paraffin blocks. Four-micrometer sections were cut, mounted on Fisherbrand Superfrost Plus glass slides (Fisher Scientific, Pittsburgh, PA), and stained with hematoxylin & eosin (Fisher Scientific) or anti-CD19.
Statistical analysis
For parametric tests, data were assessed for normality using the Kolmogorov-Smirnov test. Normally distributed values were compared using the unpaired 2-sided Student t test. Correlations between continuous and categorical variables were assessed using the Mann-Whitney U-test. All statistical tests were 2 sided, and p < 0.05 indicated significance. All analyses were performed with Prism 7 (Graphpad, La Jolla, CA).
Standard protocol approvals and registrations
All experimental animals were maintained in a specific pathogen-free facility at the University of Texas (UT) Southwestern Medical Center. All protocols involving mice handling were approved by the UT Southwestern animal care facility.
Data availability
Data not shown will be shared by request.
Results
The mice compared with C57BL/6 wild-type (WT) control mice ( figure 1A ). Cre recombination efficiency is incomplete 16 and determined mostly by the nucleotide sequence in the spacer region of the lox site. Also, there is a negative correlation between the Cre/lox recombination efficiency and the length of DNA between the 2 lox sites. As stated above, other investigators found a deletion efficiency between 75% and 80% in BM-derived pre-B cells and approximately 90% in splenic B cells. with MOG p35-55 . No significant differences regarding the EAE disease incidence, severity, or phenotype were observed between the mouse strains (figure 1B and table) . α4-integrin fl/fl mice were also used as controls and showed similar disease activity (data not shown).
α4-integrin expression on splenic B cells affects antigen-specific CD4 + T-cell proliferation It was previously demonstrated that α4-integrin can participate in costimulation of CD4 + T cells. 18, 19 Yet other investigators showed that anti-CD49d plus anti-CD3/anti-CD28-coated polystyrene beads induced significantly greater T-cell proliferation than anti-CD3/anti-CD28 polystyrene beads alone. 20 To test the effect of α4-integrin ablation on the capability of CD19 + B cells to present antigen to antigen-reactive CD4 + T cells, flow cytometric proliferation assays were performed. CD4 + T-cell recall responses to MOG p35-55 in spleens were significantly diminished in CD19.Cre +/− α4-integrin fl/fl mice ( figure 1C ). However, in LNs, we did not observe any difference in CD4 + T-cell proliferation between CD19.Cre +/− α4-integrin fl/fl mice and C57BL/6 WT control mice ( figure 1D ). + B cells in the CNS during maximum EAE disease activity was comparable between both mouse strains. Lymphocytes were immunophenotyped by multiparameter flow cytometry. The number, appearance, and architecture of germinal centers in lymph nodes of (G and H) C57BL/6 WT control mice were comparable to those in (I and J) CD19.Cre +/− α4-integrin fl/fl mice. Panels G and I were stained with hematoxylin & eosin, and panels H and J were stained with anti-CD19. Magnification for G-J is ×4. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. CFSE = carboxyfluorescein succinimidyl ester.
In both mouse strains, T-cell proliferation was substantial. Our observations appear to differ from those of other investigators, who showed that B cells do not present MOG p35-55 to T cells. 21 The Methods section of that article states that "…B cells were magnetically activated cell sorting (MACS; Miltenyi Biotec, Bergisch Gladbach, Germany)-separated from lymph nodes or spleens." Thus, a differential capability of B cells isolated from either LNs or spleens on MOG peptide presentation may not have been fully tested.
The number of B cells in the CNS during active MOG p35-55 -induced EAE is diminished in CD19.Cre +/2 α4-integrin fl/fl mice To examine the effect of α4-integrin deletion in CD19 + B cells on the ability of B lymphocytes to enter the CNS, cells were isolated from brains and spinal cords by Percoll gradient and analyzed by multiparameter flow cytometry. As MOG p35-55 -induced EAE is a T-cell-mediated form of EAE, the number of CD3 + T cells was also assessed by the same method. At maximum disease activity (days [13] [14] [15] The ( figure 2G) . Also, the expression of the costimulator molecules CD80 and CD86 and the first apoptosis signal receptor CD95 was comparable in brain-derived B cells from CD19.Cre +/− α4-integrin fl/fl mice and C57BL/6 WT controls ( figure 2H ). − CD138 + PCs, was assessed by multiparameter flow cytometry during acute MOG p35-55 -induced EAE at day 13 during early active EAE (figure 2I), day 19 during maximum EAE disease activity (figure 2J), and day 29 during chronic EAE (figure 2K) after active induction or EAE with MOG p35-55 and was found to be similar in CD19.Cre +/− α4-integrin fl/fl mice and C57BL/6 WT controls at all time points. A gating strategy used to identify some of the B-cell subsets is shown in figure 3 .
The composition of B-cell subsets in primary and secondary lymphoid organs of CD19.Cre
α4-integrin fl/fl mice is similar to those of WT control mice during MOG p35-55 -induced EAE To assess the effect of α4-integrin ablation on CD19 + B cells on B-cell phenotypes in lymphoid organs, innate and adaptive B-lymphocyte subsets were characterized by flow cytometry. low/-plasma blast (PB), and B220 − CD138 + plasma cells (PC) was similar in both mouse strains at (I) day 13 during early active EAE, (J) day 19 during maximum EAE disease activity, and (K) day 29 during chronic EAE. Lymphocytes were immunophenotyped by multiparameter flow cytometry. A gating strategy used to identify some of the B-cell subsets is shown in Figure 3 . **p < 0.01.
We were unable to detect a change in composition of mice and C57BL/6 WT controls at day 13 during early active EAE in the BM (figure 4A), LNs ( Figure 4B ), and spleen ( figure 4C ).
Serum soluble inflammatory markers are unchanged in CD19.Cre +/2 α4-integrin fl/fl mice during different stages of MOG p35-55 -induced EAE Deletion of α4-integrin on CD19 + B cells diminishes the ability of CD19 + B cells to enter the CNS during acute MOG p35-55 -induced EAE ( figure 1E ). It is conceivable that inflammatory B cells accumulate in peripheral blood, altering the inflammatory milieu in that compartment. This was observed in patients with MS treated with natalizumab. 22 We found that the serum expression of the cytokines IL-17A (figure 5A), IL-10 ( Figure 5B ), IL-4 ( Figure 5C α4-integrin fl/fl mice during different stages of MOG p35-55 -induced EAE To further investigate whether the sequestration of CD19 + B cells through deletion of α4-integrin affects their activation, proliferation, and antibody secretion, IgM and IgG levels in serum were determined by ELISA. Serum levels of IgM (figure 5F) and IgG (figure 5G) as measured by ELISA were also similar between CD19.Cre +/− α4-integrin fl/fl mice and C57BL/6 WT control mice on days 13, 19, and 29 of MOG p35-55 -induced EAE. Given that the absolute levels of IgM and IgG were similar between the mouse strains, and that other investigators previously showed that B cells from mice on the C57BL/6 background do not readily recognize MOG p35-55 , 21 we did not test the serum levels of MOGp 35-55 -specific IgM or IgG. 
Discussion
There is accumulating evidence to suggest that B cells and myelin-specific antibodies play crucial roles in the pathogenesis of MS. Whether B-cell depletion mediates its beneficial effects in patients with MS through B cells in the periphery, in the CNS, or both is currently not completely understood.
Other investigators investigated the role of α4-integrin deficiency in CD19 + B cells in EAE. 23 These investigators showed that B-cell very late activation antigen-4-deficient mice developed more severe clinical disease than control mice after active induction of EAE with MOG p35-55 mice. 25 It is not stated whether mice were heterozygous or homozygous for CD19.cre or a mixture of both. As stated in the Methods section, CD19.Cre +/+ mice behave functionally very similarly to B-cell-deficient mice, which develop more severe EAE when immunized with MOG p35-55 . 26 We found one potentially meaningful biological difference between CD19.Cre +/− α4-integrin fl/fl mice and C57BL/6 control mice. There was decreased MOG p35-55 -specific CD4 + T-cell proliferation in spleens, which is an expected result, given that α4-integrin can participate in costimulation of CD4 + T cells. 18, 19 The observation that CD19 + B cells of CD19.Cre +/− α4-integrin fl/fl mice did deplete α4-integrin and that they were significantly less capable of entering the CNS after mice were immunized with MOG p35-55 suggests 3 interpretations: (1) Antigen-activated B cells contribute to disease burden in EAE in a seemingly dose-dependent manner, (2) they do not absolutely require recognition of a CNS autoantigen or a mimic thereof to do so, and (3) they do not require full α4-integrin-mediated access to the CNS to exacerbate disease. The first interpretation is supported by work of other investigators who have previously demonstrated that B-celldeficient C57BL/6 mice are resistant to active rMOG-induced EAE 26 and that the administration of a B-cell-depleting monoclonal antibody prevents or reverses established rMOGinduced EAE in C57BL/6 mice. 21 Weber and colleagues 21 further showed that B-cell depletion results in a reduction of MOG p35-55 -specific Th1 and Th17 cells. Our own data suggest that the differentiation of MOG p35-55 -specific T cells to become encephalitogenic does not absolutely require the presentation of autoantigen, but is likely driven by other B-cell factors, including soluble inflammatory mediators. The third interpretation of this experiment is supported by our demonstration that B cells from CD19.Cre +/− α4-integrin fl/fl mice are significantly impaired in their ability to enter the CNS ( figure 1E ). Finally, it should be emphasized that our findings do not conclusively rule out a role of antigen-specific B cells in the CNS on the course of CNS autoimmunity, as threshold effects may be difficult to detect with the EAE experiments that were conducted.
Our data suggest that the beneficial effects of anti-CD20 therapies in patients with MS are mediated through their effects on peripheral B cells. We also conclude that benefits observed in patients with MS during anti-α4-integrin therapy are likely not predominantly due to its effect of suppressing the migration of B cells into the CNS. The interpretation of our findings should be limited to early forms of MS, as the EAE model that was used and the observation period that was used do not provide insight into late or progressive forms of CNS autoimmunity. Magliozzi et al 27 were the first investigators to show that some patients with secondaryprogressive MS develop lymphoid tissue in the meninges that resemble B-cell follicles in secondary lymphoid organs. B cells in these structures may be susceptible to anti-CD20 therapies with monoclonal antibodies or small molecules, and it is conceivable that their depletion may benefit patients afflicted with that MS phenotype.
